CellEmax
Valbonne / 660 Rte des Lucioles
Creation:|
The lack of efficacy of targeted therapies in oncology is attributed to non-genetic molecular resistance mechanisms. These mechanisms represent potential targets for therapeutic combinations. Our technology, which combines live-cell imaging and machine learning, enables the identification of these molecular targets and provides the key to designing rational therapeutic combinations, ensuring the success of developing immunotherapies. Our startup, CellEmax, will market these targets and provide access to our cutting-edge technologies. |
|||||||||
| Business axis : |
Medicine E-health
|
||||||||
| Category : | TPE | ||||||||
| Legal form : | |||||||||
| Number of employees : | 7 | ||||||||
| Website : | |||||||||
| Turnover : |
0.00 K€ |
||||||||
| Reference technologies : | |||||||||